Acute pancreatitis is defined as an acute inflammatory process of the pancreas. The incidence of acute pancreatitis in the general population shows geographical variation. Incidence rates reported in the literature range between 4 and up to \>100 cases per 100,000 person-years in the western world ([@B1][@B2]--[@B3]). Data from western countries suggest that the incidence of acute pancreatitis has been increasing over the last 40 years ([@B3]).

The reason for this increase is unknown. However, a concurrent trend has been the rapid, worldwide increase in type 2 diabetes and obesity. Several clinical factors associated with type 2 diabetes and obesity are known or putative risk factors for acute pancreatitis (e.g., gallstone disease). Therefore, it can be hypothesized that in type 2 diabetic patients the risk of acute pancreatitis might be higher than that for the general population ([@B2]). Studies exploring whether diabetes or antidiabetic treatment may act as risk factors for the development of acute pancreatitis have been limited so far ([@B2],[@B4][@B5]--[@B6]). Three observational studies reported an approximately two- to threefold increased risk of acute pancreatitis among diabetic patients ([@B2],[@B4],[@B5]). The purpose of this study was to further assess the risk of acute pancreatitis in association with type 2 diabetic patients and antidiabetic treatment.

RESEARCH DESIGN AND METHODS
===========================

This population-based cohort study with a nested case-control analysis was based on information from The Health Improvement Network (THIN). THIN is a U.K. longitudinal primary care medical record database that includes diagnostic and prescribing data recorded by general practitioners as part of their routine clinical care. The population in THIN is representative of the general population in the U.K.

The source population included all individuals aged 20--79 years in THIN enrolled for at least 2 years with their general practitioner, who had the first prescription ever recorded in the computer files \>1 year before entering the study and at least one health contact in the last 2 years. The study period was from 1 January 1996 to 31 December 2006. We excluded all individuals with a history of cancer (other than nonmelanoma skin cancer) or pancreatic disease before entering the study. Individuals aged ≥70 years with a follow-up \>1 year and less than two health contacts during their follow-up period were removed because data completeness is most likely seriously deficient in this subgroup. We identified two cohorts within this source population: the type 2 diabetes cohort and the (diabetes-free) general population cohort.

We ascertained all patients within the study base with a READ code of diabetes recorded in the database. Based on type-specific READ codes (i.e., those that denote explicitly the type of diabetes), the age at diagnosis, and the lifetime history of antidiabetic pharmacological treatment we were able to classify the initial 92,701 patients with a recorded diagnosis of diabetes into 7,176 (7.74%) patients with type 1 and 85,525 (92.26%) with type 2 diabetes. The latter comprised the type 2 diabetes cohort ([Fig. 1](#F1){ref-type="fig"}).
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The general population cohort included 200,000 individuals randomly sampled from the source population and frequency-matched by age, sex, and calendar year to the diabetes cohort. The same eligibility criteria as for the diabetes cohort were applied with the additional condition that patients had to be free of a recorded diagnosis of diabetes.

Follow-up for acute pancreatitis
--------------------------------

We followed all members from the diabetes and the general population cohort from the date when an individual met all eligibility criteria until the earliest occurrence of one of the following end points: a recorded diagnosis of acute pancreatitis, cancer, his or her 80th birthday, death, or the end of the study period. We reviewed the computerized patient profiles with free text comments of all individuals identified as potentially having cases of pancreatitis. After this manual review of all potential cases, we classified cases as "not confirmed" (and subsequently excluded them from the study) in situations in which acute pancreatitis was initially suspected but ruled out later on, and in individuals who met an exclusion criterion (i.e., cancer or prevalent case of pancreatic disease). All remaining cases were considered as "confirmed" incident cases, most cases (88%) being well documented; i.e., the episode of acute pancreatitis either included a documented emergency admission and/or hospitalization or the diagnosis had been made by a specialist.

For a random sample of 50 case subjects, we also sent out a questionnaire to the patient\'s general practitioners to confirm the diagnosis and to provide all available additional data related to that event. We received valid information (questionnaires and additional clinical documents) for 44 case subjects, corresponding to a 88% response rate.

Statistical analyses
--------------------

### Cohort analysis.

Person-time at risk in each study cohort was classified across strata by age, sex, and calendar year. Age- and sex-specific incidence rates of acute pancreatitis were calculated using the corresponding person-time at risk in each cohort as denominator.

Crude and adjusted incidence rate ratios (IRRs) with 95% CIs associated with diabetes were computed using a Poisson regression model with age, sex, and calendar year included in the model. Potential interactions were studied by including these variables in the model as interaction terms.

### Nested case-control analysis.

In addition, a nested case-control analysis was performed to evaluate in more detail the role of diabetes and of antidiabetic drugs on the risk of acute pancreatitis. The individuals with confirmed cases of acute pancreatitis from both cohorts were used as case subjects and their date of diagnosis was used as the index date.

Control subjects were randomly sampled from the two study cohorts in which pancreatitis case subjects were ascertained. A group of 5,000 control subjects was randomly selected from the list of eligible person-time and frequency-matched to the case subjects on sex, same age (±1 year), and calendar year.

For all case and control subjects we ascertained demographic (age, sex, Townsend deprivation index \[[@B7],[@B8]\], and BMI) and lifestyle factors (e.g., smoking and alcohol intake) as well as general comorbidity (e.g., chronic conditions and previous gastrointestinal diseases) at the index date. In addition, we ascertained exposure to antidiabetic drugs using separate exposure variables for insulin, metformin, sulfonylureas, thiazolidinediones, and other antidiabetic drugs (i.e., acarbose, repaglinide, and nateglinide) and other common drugs or drug classes including antibiotics, antidepressants, corticosteroids, acid-suppressing drugs, nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, paracetamol, antihypertensive agents, lipid-lowering drugs, and hormone replacement therapy. Individuals were classified as current users if they were taking the drug at the index date or had taken it within the previous 30 days. Those not currently exposed but who had used the drug within the year before the index date were classified as past users. Everyone else was classified as nonuser. We also explored the effect of drug duration (\<1 year, 1--3 years, and \>3 years) on the risk of acute pancreatitis.

Unconditional regression analyses were used to assess odds ratios (ORs) together with 95% CIs. The fully adjusted model included the matching variables age and sex and the following predictors of acute pancreatitis: smoking status, alcohol intake, ischemic heart disease, previous gastrointestinal disease, exposure to antidiabetic drugs, antibiotics, acid-suppressing drugs, NSAIDs (including aspirin and coxibs), paracetamol, and antihypertensive drugs, BMI, and Townsend deprivation index. All analyses were done using Stata SE 10.0 (StataCorp, College Station, TX).

RESULTS
=======

Cohort analysis
---------------

A total of 85,525 patients with type 2 diabetes were included for the cohort analyses together with the 200,000 frequency-matched individuals from the general population. The average ± SD age at start date in the type 2 diabetes and the general population cohort was 61.2 ± 11.4 and 59.5 ± 12.8 years, respectively; 43.7% of subjects in the diabetes and 43.5% in the general population cohort were female. The total amount of follow-up time was 325,990 person-years in the type 2 diabetes and 807,453 person-years in the general population cohort, corresponding to an average follow-up time of 3.8 and 4.0 years, respectively. During follow-up, we identified a total of 456 potential cases of acute pancreatitis, 261 in the general population and 195 in the diabetes cohort.

After manual review of the patients\' computerized profiles, we classified 35 cases as not confirmed cases (7.7%). The remaining 421 cases were classified as confirmed cases.

In the validation study, 2 of the 44 cases in individuals for whom we received valid information were considered as not confirmed by the general practitioners. This resulted in a confirmation rate of 95.5% in the validation study. These 2 not confirmed cases were subsequently excluded, leaving 419 cases of acute pancreatitis included in the final analyses (243 cases in the general population and 176 cases in the diabetes cohort). The corresponding crude incidence rate of acute pancreatitis was 30.1 per 100,000 person-years in the general population and 54.0 per 100,000 person-years in the diabetes cohort. Incidence rates stratified by age and sex for the diabetic and the general population cohort are presented in [Table 1](#T1){ref-type="table"}.

###### 

Incidence rate of acute pancreatitis by age and sex in the general population without diabetes and in type 2 diabetic patients (cohort analysis)

  Age strata                           Person-years                                                       Cases   Incidence rate per 100,000 person-years (95% CI)
  ------------------------------------ ------------------------------------------------------------------ ------- --------------------------------------------------
  General population (*n* = 200,000)                                                                              
      Women                                                                                                       
          20--39 years                 25,300                                                             5       19.8 (6.4--46.1)
          40--59 years                 105,655                                                            22      20.8 (13--31.5)
          60--69 years                 105,824                                                            27      25.5 (16.8--37.1)
          70--79 years                 116,742                                                            41      35.1 (25.2--47.6)
          Overall                      353,521                                                            95      26.9 (21.7--32.8)
      Men                                                                                                         
          20--39 years                 25,732                                                             5       19.4 (6.3--45.3)
          40--59 years                 157,241                                                            46      29.3 (21.4--39)
          60--69 years                 146,542                                                            41      28.0 (20--37.9)
          70--79 years                 124,416                                                            56      45.0 (34--58.4)
          Overall                      453,932                                                            148     32.6 (27.5--38.3)
      Total                            807,453                                                            243     30.1 (26.4--34.1)
  Type 2 diabetes (*n* = 85,525)                                                                                  
      Women                                                                                                       
          20--39 years                 5,105                                                              4       78.4 (21.3--200.6)
          40--59 years                 40,585                                                             21      51.7 (32--79.1)
          60--69 years                 45,377                                                             27      59.5 (39.2--86.5)
          70--79 years                 50,057                                                             22      43.9 (27.5--66.5)
          Overall                      141,125                                                            74      52.4 (41.1--65.8)
      Men                                                                                                         
          20--39 years                 4,479                                                              2       44.7 (5.4--161.3)
          40--59 years                 61,109                                                             35      57.3 (39.8--79.6)
          60--69 years                 63,979                                                             32      50.0 (34.2--70.6)
          70--79 years                 55,299                                                             33      59.7 (41--83.8)
          Overall                      184,865                                                            102     55.2 (44.9--66.9)
      Total                            325,990                                                            176     54.0 (46.3--62.5)
                                       IRR~diabetes~ 1.79 (1.48--2.18)[\*](#TF1-1){ref-type="table-fn"}           

\*Unadjusted estimate of acute pancreatitis in type 2 diabetic patients compared with the general population.

These results translate into a 79% increased risk of a first-ever episode of acute pancreatitis among type 2 diabetic patients compared with the general population (crude IRR 1.79 \[95% CI 1.48--2.18\]). Because the two cohorts were frequency matched, we obtained very similar results when we estimated the age-, sex-, and calendar year--adjusted IRR by fitting a Poisson regression model (1.77 \[1.46--2.15\]).

Increasing age was associated with a higher risk of acute pancreatitis in the overall cohort. Compared with those aged \<40 years, the risk of acute pancreatitis was increased in those aged 40--59, 60--69, and ≥70 years by 17, 20, and 50%, respectively (*P*~trend~ = 0.02).

Furthermore, we explored the potential effect modification of the association between diabetes and acute pancreatitis by age. We found a significant trend toward a decreasing association between diabetes and acute pancreatitis with increasing age (*P* = 0.019). We also evaluated whether sex could modify the association between diabetes and acute pancreatitis, but the corresponding statistical test was not significant.

Nested case-control analysis
----------------------------

After adjustment for various demographic and lifestyle variables, comorbidities, and drug exposure, patients with type 2 diabetes had a nonsignificantly increased risk of acute pancreatitis compared with those free of diabetes (adjusted OR 1.37 \[95% CI 0.99--1.89\]) ([Table 2](#T2){ref-type="table"}). When we analyzed separately the risk associated with incident diabetes (diabetes first diagnosed during the study period) and prevalent diabetes (diabetes first diagnosed before the study period), the adjusted ORs were virtually the same (1.38 \[0.98--1.94\] and 1.34 \[0.90--2.01\], respectively). Furthermore, to explore the possibility of an increased risk of acute pancreatitis around the time of the first diagnosis of diabetes, we further divided our cohort of incident diabetic patients according to the time elapsed since the first diagnosis of diabetes. During the 1st year after the diagnosis of diabetes, the risk was somewhat higher (1.61 \[1.00--2.60\]) than thereafter (1.26 \[0.85--1.88\]). This difference, however, did not reach statistical significance (*P* = 0.38).

###### 

Risk of acute pancreatitis associated with diabetes, antidiabetic drugs, and other factors (nested case-control analysis)

                                                             Case subjects   Control subjects   Odds ratio (95% CI)   
  ---------------------------------------------------------- --------------- ------------------ --------------------- --------------------
  *n*                                                        419             5,000                                    
  Smoking                                                                                                             
      Nonsmoker                                              128 (30.5)      1,795 (35.9)       1 (referent)          1 (referent)
      Smoker                                                 71 (16.9)       623 (12.5)         1.60 (1.18--2.17)     1.48 (1.06--2.06)
      Former smoker                                          175 (41.8)      1,909 (38.2)       1.29 (1.01--1.63)     1.14 (0.89--1.47)
      Unknown                                                45 (10.7)       673 (13.5)         0.94 (0.66--1.33)     1.18 (0.81--1.72)
  Alcohol use                                                                                                         
      Nondrinker                                             200 (47.7)      2,082 (41.6)       1 (referent)          1 (referent)
      Between 1 and 7/week                                   92 (22.0)       1,236 (24.7)       0.77 (0.60--1.00)     0.86 (0.66--1.13)
      Between 8 and 29/week                                  58 (13.8)       895 (17.9)         0.67 (0.50--0.91)     0.75 (0.54--1.03)
      ≥30/week                                               45 (10.7)       291 (5.8)          1.61 (1.14--2.27)     1.49 (1.02--2.18)
      Unknown                                                24 (5.7)        496 (9.9)          0.50 (0.33--0.78)     0.72 (0.43--1.19)
  Diabetes                                                                                                            
      No                                                     243 (58.0)      3,489 (69.8)       1 (referent)          1 (referent)
      Yes                                                    176 (42.0)      1,511 (30.2)       1.67 (1.36--2.05)     1.37 (0.99--1.89)
  Antidiabetic drugs                                                                                                  
      Insulin                                                                                                         
          Nonuse (366+)                                      399 (95.2)      4,650 (93.0)       1 (referent)          1 (referent)
          Current use (0--30)                                19 (4.5)        328 (6.6)          0.68 (0.42--1.08)     0.35 (0.20--0.61)
          Past use (31--365)                                 1 (0.2)         22 (0.4)           0.53 (0.07--3.94)     0.31 (0.04--2.43)
      Metformin                                                                                                       
          Nonuse (366+)                                      328 (78.3)      4,261 (85.2)       1 (referent)          1 (referent)
          Current use (0--30)                                75 (17.9)       655 (13.1)         1.49 (1.14--1.94)     0.81 (0.56--1.15)
          Past use (31--365)                                 16 (3.8)        84 (1.7)           2.47 (1.43--4.27)     1.18 (0.62--2.25)
      Sulfonylureas                                                                                                   
          Nonuse (366+)                                      334 (79.7)      4,460 (89.2)       1 (referent)          1 (referent)
          Current use (0--30)                                69 (16.5)       474 (9.5)          1.94 (1.48--2.56)     1.25 (0.86--1.80)
          Past use (31--365)                                 16 (3.8)        66 (1.3)           3.24 (1.85--5.65)     2.58 (1.34--4.96)
      Thiazolidinediones                                                                                              
          Nonuse (366+)                                      396 (94.5)      4,864 (97.3)       1 (referent)          1 (referent)
          Current use (0--30)                                20 (4.8)        117 (2.3)          2.10 (1.29--3.41)     1.25 (0.72--2.16)
          Past use (31--365)                                 3 (0.7)         19 (0.4)           1.94 (0.57--6.58)     1.23 (0.33--4.66)
      Other antidiabetic drugs                                                                                        
          Nonuse (366+)                                      412 (98.3)      4,962 (99.2)       1 (referent)          1 (referent)
          Current use (0--30)                                4 (1.0)         27 (0.5)           1.78 (0.62--5.12)     1.23 (0.40--3.78)
          Past use (31--365)                                 3 (0.7)         11 (0.2)           3.28 (0.91--11.82)    2.56 (0.61--10.66)
  Gastrointestinal disease[†](#TF2-2){ref-type="table-fn"}                                                            
      No                                                     107 (25.5)      2,318 (46.4)       1 (referent)          1 (referent)
      Yes                                                    312 (74.5)      2,682 (53.6)       2.52 (2.01--3.16)     1.91 (1.50--2.45)
  BMI                                                                                                                 
      20--24 kg/m^2^[\*](#TF2-1){ref-type="table-fn"}        95 (22.7)       1,242 (24.8)       1 (referent)          1 (referent)
      \<20 kg/m^2^                                           15 (3.6)        164 (3.3)          1.20 (0.68--2.11)     1.13 (0.63--2.02)
      25--29 kg/m^2^                                         154 (36.8)      1,809 (36.2)       1.11 (0.85--1.45)     0.99 (0.75--1.31)
      ≥30 kg/m^2^                                            131 (31.3)      1,337 (26.7)       1.28 (0.97--1.69)     0.92 (0.68--1.24)
      Unknown                                                24 (5.7)        448 (9.0)          0.70 (0.44--1.11)     1.01 (0.60--1.72)
  Paracetamol                                                                                                         
      Nonuse (366+)                                          240 (57.3)      3,620 (72.4)       1 (referent)          1 (referent)
      Current use (0--30)                                    105 (25.1)      732 (14.6)         2.16 (1.70--2.76)     1.65 (1.25--2.18)
      Past use (31--365)                                     74 (17.7)       648 (13.0)         1.72 (1.31--2.26)     1.38 (1.02--1.86)
  ACE inhibitors                                                                                                      
      Nonuse (366+)                                          3,892 (77.8)    280 (66.8)         1 (referent)          1 (referent)
      Current use (0--30)                                    978 (19.6)      124 (29.6)         1.76 (1.41--2.20)     1.37 (1.04--1.80)
      Past use (31--365)                                     130 (2.6)       15 (3.6)           1.60 (0.93--2.77)     1.12 (0.61--2.04)

Data are *n* (%) unless otherwise indicated.

\*Adjusted for all variables included in the table plus age, sex, Townsend index, ischemic heart disease, and exposure to antibiotics, H~2~ blockers, proton pump inhibitors, NSAIDs (including aspirin and coxibs), and other antihypertensive drugs.

†Includes gallstones, biliary tract disease, cholecystitis, gastroenteritis, abdominal pain, and others.

Among users of antidiabetic drugs, current users of insulin were at a decreased risk of acute pancreatitis (adjusted OR 0.35 \[95% CI 0.20--0.61\]) compared with nonusers. Moreover, past use of sulfonylureas was associated with a significant risk increase of acute pancreatitis compared with that for nonusers (2.58 \[1.34--4.96\]). Otherwise, exposure to antidiabetic drugs was not materially associated with the risk of acute pancreatitis ([Table 2](#T2){ref-type="table"}).

We also explored the impact of treatment duration among current antidiabetic drug users ([Table 3](#T3){ref-type="table"}). A reduced risk of acute pancreatitis was observed across all different strata of insulin duration with a similar magnitude of association, corresponding to a 60--70% reduction in the acute pancreatitis risk. Of interest, metformin and sulfonylureas, which overall did not seem to be associated with acute pancreatitis, were associated with decreased and increased risks, respectively, but only among long-term users of these drugs. The other antidiabetic drugs studied (thiazolidinediones and others) were not found to be associated with acute pancreatitis in any of these analyses although their numbers were considerably smaller.

###### 

Risk of acute pancreatitis and duration of current use of antidiabetic drugs (nested case-control analysis)

                                               Case subjects   Control subjects   OR (95% CI)[\*](#TF3-1){ref-type="table-fn"}
  -------------------------------------------- --------------- ------------------ ----------------------------------------------
  *n*                                          419             5,000              
  Insulin                                                                         
      Nonuse[†](#TF3-2){ref-type="table-fn"}   399 (95.2)      4,650 (93.0)       1 (referent)
      Short duration (\<1 year)                7 (1.7)         82 (1.6)           0.41 (0.17--1.00)
      Mid duration (1--3 years)                5 (1.2)         88 (1.8)           0.34 (0.13--0.91)
      Long duration (\>3 years)                7 (1.7)         158 (3.2)          0.30 (0.13--0.68)
  Metformin                                                                       
      Nonuse[†](#TF3-2){ref-type="table-fn"}   328 (78.3)      4,261 (85.2)       1 (referent)
      Short duration (\<1 year)                26 (6.2)        213 (4.3)          0.88 (0.53--1.47)
      Mid duration (1--3 years)                31 (7.4)        237 (4.7)          0.93 (0.58--1.49)
      Long duration (\>3 years)                18 (4.3)        205 (4.1)          0.50 (0.28--0.91)
  Sulfonylureas                                                                   
      Nonuse[†](#TF3-2){ref-type="table-fn"}   334 (79.7)      4,460 (89.2)       1 (referent)
      Short duration (\<1 year)                13 (3.1)        125 (2.5)          0.81 (0.42--1.57)
      Mid duration (1--3 years)                25 (6.0)        156 (3.1)          1.20 (0.70--2.03)
      Long duration (\>3 years)                31 (7.4)        193 (3.9)          1.66 (1.01--2.74)
  Thiazolidinediones                                                              
      Nonuse[†](#TF3-2){ref-type="table-fn"}   396 (94.5)      4,864 (97.3)       1 (referent)
      Short duration (\<1 year)                11 (2.6)        57 (1.1)           1.28 (0.61--2.68)
      Mid duration (1--3 years)                7 (1.7)         46 (0.9)           1.19 (0.49--2.90)
      Long duration (\>3 years)                2 (0.5)         14 (0.3)           1.27 (0.23--6.89)
  Other antidiabetic drugs                                                        
      Nonuse[†](#TF3-2){ref-type="table-fn"}   412 (98.3)      4,962 (99.2)       1 (referent)
      Short duration (\<1 year)                1 (0.2)         9 (0.2)            1.24 (0.13--11.82)
      Mid duration (1--3 years)                1 (0.2)         8 (0.2)            0.94 (0.11--8.14)
      Long duration (\>3 years)                2 (0.5)         10 (0.2)           1.85 (0.34--10.10)

Data are *n* (%) unless otherwise indicated.

\*Adjusted for all variables included in the table plus those in the fully adjusted model of [Table 2](#T2){ref-type="table"}.

†Baseline category.

Among individuals with diabetes, metformin and sulfonylureas were the two most commonly prescribed drugs, followed by insulin. Among control subjects, a total of 73% of diabetic patients were receiving specific antidiabetic drug treatment at the index date. The remaining 27% were not currently receiving antidiabetic drug therapy. Treated diabetic patients had an adjusted OR of 1.19 \[95% CI 0.91--1.55\] for acute pancreatitis compared with that for the general population, whereas those not receiving antidiabetic drug treatment (1.49 \[1.06--2.08\]) seemed to concentrate the overall increased risk associated with diabetes. However, this difference was not statistically significant (*P* = 0.21). In addition, the risk of acute pancreatitis was significantly increased among current smokers, those taking ≥30 units of alcohol per week, individuals with a previous history of gastrointestinal disease, and current users of paracetamol and ACE inhibitors ([Table 2](#T2){ref-type="table"}).

CONCLUSIONS
===========

The results of this study confirm the excess risk of acute pancreatitis associated with type 2 diabetes previously reported in other observational studies ([@B2],[@B4],[@B5]). In fact, the cohort analysis yielded a statistically significant 77% increased risk of acute pancreatitis associated with a prior history of diabetes. This translates into ∼23 additional cases for every 100,000 patients with diabetes each year. However, the magnitude of this association was reduced when it was adjusted for other risk factors in a multivariate model and became borderline significant in the nested-case control analysis.

This association of an increased risk of acute pancreatitis and type 2 diabetes seems more pronounced at younger ages and has already been observed in a recent retrospective cohort study based on information from a U.S, health claims database ([@B2]). We were also able to assess how antidiabetic drugs might influence this association. Interestingly, use of insulin and long-term use of metformin were associated with a decreased risk of pancreatitis, as opposed to long-term use of sulfonylureas, which seems to increase the risk. In a previous case-control study, Blomgren et al. ([@B4]) found that the sulfonylurea glyburide increased the risk of acute pancreatitis, but neither insulin nor metformin seemed to lower the risk. In fact, there are reports of cases of acute pancreatitis in patients using metformin after an episode of acute renal failure ([@B9],[@B10]). To the best of our knowledge, this is the first study suggesting a reduced risk associated with these antidiabetic drugs. We think it is premature to propose potential mechanisms before these findings are replicated. Overall, when we analyzed the risk of pancreatitis among treated and not treated diabetic patients separately, we observed that the greatest risk appeared among those without antidiabetic pharmacotherapy, who represent a quarter of our diabetic population. This result may be partially due to a slight increased risk of acute pancreatitis immediately after the diagnosis of diabetes, although this assumption could not be confirmed in our study.

Our data from the general population cohort could replicate results from previous epidemiological studies showing that the incidence of acute pancreatitis rises with increasing age and tends to be higher in men than women ([@B1],[@B11],[@B12]). Furthermore, the incidence rate found in the general population is also in line with results from a recent study from England ([@B13]).

Among other risk factors studied, we found that previously reported risk factors such as smoking ([@B5]), alcohol use ([@B1],[@B14]), or use of ACE inhibitors ([@B15],[@B16]) were replicated in our study. Exposure to paracetamol was also associated with an increased pancreatitis risk as in previous studies ([@B15]).

The current study has several strengths. First, it is based on a large database with documented high data quality and completeness ([@B17][@B18]--[@B19]). Second, detailed information on important lifestyle factors, comorbidities, concomitant drug therapies, and BMI was available. Third, we reviewed the patient profiles of computer-detected potential cases with all additional information included in free text comments and validated the case status in a random sample by accessing the original medical records available in general practitioner offices. Fourth, we could replicate results from other studies regarding the association of various comorbidities and/or exposures and the risk of acute pancreatitis.

However, the study also has its limitations. Although we adjusted our analyses for various potential risk factors of acute pancreatitis, it is possible that there is still some residual confounding we did not account for. Moreover, throughout this report we present results for a large number of factors including lifestyle, comorbidity, and drug therapies (as well as different drug durations). This implicit multiple testing could be inflating the study-wide type I error. One should keep this in mind, when interpreting these results, and even more so in the case of subanalyses that do not belong to the main purpose of the study. However, because of the exploratory nature of these findings, we did not deem it necessary to adjust for multiple comparisons.

In summary, we have shown that type 2 diabetes may be associated with a slight increase in the risk of acute pancreatitis. We have also found that use of insulin in type 2 diabetes might be associated with a reduced risk. Further research is warranted to confirm these observed associations.
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